Perampanel is a non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons. Glutamate is the primary ...

Fycompa (perampanel) is currently indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

Eisai's epilepsy medication, Fycompa, was approved by the FDA in October of last year, however, the company is still waiting for the US Drug Enforcement Administration (DEA) to classify the drug ...

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...

Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY IncreaseRecord Revenues Driven by Continued Organic Growth in its Rare ...